Activation of mTORC1 signaling pathway in AIDS-related lymphomas

American Journal of Pathology

Volumn 175, Issue 2, 2009, Pages 817-824

  El Salem, Mouna ^a   Raghunath, Puthiyaveettil N ^a   Marzec, Michal ^a   Liu, Xiaobin ^a   Kasprzycka, Monika ^a   Robertson, Erle ^a   Wasik, Mariusz A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE SYK; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; EPSTEIN BARR VIRUS; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LYMPHADENOPATHY; LYMPHOMA; NONHODGKIN LYMPHOMA; PHENOTYPE; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; VIRUS INFECTION; WESTERN BLOTTING;

EID: 68449090866     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080451     Document Type: Article

References (49)

1. Wood C, Harrington W, Jr.: AIDS related lymphomas. Cell Res 2005,15:947-952
2. Diamond C, Taylor TH, Aboumrad T, Anton-Culver H: Changes in acquired immuno-deficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 2006, 106:128-135
3. Krause J: AIDS-related non-Hodgkin's lymphomas. Microsc Res Tech 2005, 68:168-175
4. Raphael M, Borisch B, Jaffe ES: Lymphomas associated with infection by the human immune deficiency virus (HIV). In: World Health Organization Classification of Tumours, Tumours of the Hematopoietic and Lymphoid Tissues. Edited by E Jaffe, NL Harris, H Stein, J Vardiman. Lyon, IARC Press, 2001, pp 260-263
5. Sabatini DM: mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006, 6:729-734
6. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N: mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 2006, 94:195-199
7. Corradettia MN, Guan KL: Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene 2006, 25:6347-6360
8. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC, Jr., Abraham RT: Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 1996, 15:5256-5267
9. Navé BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR: Mammalian target of rapamycin is a direct target for protein kinase B: Identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999, 344:427-431
10. Sekulić A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT: A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000, 60:3504-3513
11. Tee AR, Anjum R, Blenis J: Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/ Akt-dependent and independent prosphorylation of tuberin. J Biol Chem 2003, 278:37288-37296
12. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP: Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121:179-193
13. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ: Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281
14. Hutchcroft JE, Harrison ML, Geahlen RL: B lymphocyte activation is accompanied by phosphorylation of a 72-kDa protein-tyrosine kinase. J Biol Chem 1991, 266:14846-1484
15. Darby C, Geahlen RL, Schreiber AD: Stimulation of macrophage Fc gamma RIIIA activates the receptor-associated protein tyrosine kinase Syk and induces phosphorylation of multiple proteins including p95Vav and p62/GAP-associated protein. J Immunol 1994, 152:5429-5437
16. Hutchcroft JE, Geahlen RL, Deanin GG, Oliver JM: Fc epsilon RI-mediated tyrosine phosphorylation and activation of the 72-kDa protein-tyrosine kinase, PTK72, in RBL-2H3 rat tumor mast cells. Proc Natl Acad Sci USA 1992, 89:9107-9111
17. Hutchcroft JE, Harrison ML, Geahlen RL: Association of the 72-kDa proteintyrosine kinase PTK72 with the B cell antigen receptor. J Biol Chem 1992, 267:8613-8619
18. Agarwal A, Salem P, Robbins KC: Involvement of p72syk, a protein-tyrosine kinase, in Fc gamma receptor signaling. J Biol Chem 1993, 268:15900-15905
19. Jouvin MH, Adamczewski M, Numerof R, Letourneur O, Valle A, Kinet JP: Differential control of the tyrosine kinases Lyn and Syk by the two signaling chains of the high affinity immunoglobulin E receptor. J Biol Chem 1994, 269:5918-5925
20. Kiener PA, Rankin BM, Burkhardt AL, Schieven GL, Gilliland LK, Rowley RB, Bolen JB, Ledbetter JA: Cross-linking of Fc gamma eceptor I (Fc gamma RI) and receptor II (Fc gamma RII) on monocytic cells activates a signal transduction pathway common to both Fc receptors that involves the stimulation of p72 Syk protein tyrosine kinase. J Biol Chem 1993, 268:24442-24448
21. Leseux L, HAmdi SM, Al Saati T, Capilla F, Recher C, Laurent G, Bezombes C: Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006, 108:4156-4162
22. Wlodarski P, Kasprzycka M, Liu X, Marzec M, Robertson ES, Slupianek A, Wasik MA: Activation of mTOR in transformed B lymphocyte is nutrient-dependent but independent of Akt. MEK, IGF-I, and serum. Cancer Res 2005, 65:7800-7808
23. Marzec M, Liu X, Kasprzycka M, Witkiewicz A, Raghunath PN, El-Salem M, Robertson E, Odum N, Wasik MA: IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. Blood 2008, 111:2181-2189
24. Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, Bucki R, Wlodarski P, Wasik MA: Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene 2007, 26:5606
25. El-Salem M, Raghunath PN, Marzec M, Wlodarski P, Tsai D, Hsi E, Wasik MA: Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders (PTLDs). Lab Invest 2007, 87:29-39
26. Majewski M, Korecka M, Kossev P, Li S, Goldman J, Moore J, Silberstein LE, Nowell PC, Schuler W, Shaw LM, Wasik MA: Immuno-suppressive macrolide SDZ RAD inhibits growth of human EBV-transformed B lymphocytes in vitro and in vivo; a potential novel approach to prevention and treatment of post-transplant lymphoproliferative disorders (PTLDs). Proc Natl Acad Sci USA 2000, 97:4285-4290
27. Sin SH, Roy D, Wang L, Staudt MR, Fakhari FD, Patel DD, Henry D, Harrington WJ, Jr., Damania BA, Dittmer DP: Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 2007, 109:2165-2173
28. Sakata A, Kuwahara K, Ohmura T, Inui S, Sakaguchi N: Involvement of a rapamycin-sensitive pathway in CD40-mediated activation of murine B cells in vitro. Immunol Lett 1999, 68:301-309
29. Suh JM, Song JH, Kim DW, Kim H, Chung HK, Hwang JH, Kim JM, Hwang ES, Chung J, Han JH, Cho BY, Ro HK, Shong M: Regulation of the phosphatidylinositol 3-kinase. Akt/protein kinase B, FRAP/ mammalian target of rapamycin, and ribosomal S6 kinase 1 signaling pathways by thyroid-stimulating hormone (TSH) and stimulating type TSH receptor antibodies in the thyroid gland. J Biol Chem 2003, 278:21960-21971
30. Wing LY, Chen HM, Chuang PC, Wu M-H, Tsai SJ: The mTOR-S6K1 but not PI3K-Akt signaling is responsible for fibroblast growth factor-9-induced cell proliferation. J Biol Chem 2005, 280:19937-19947
31. Shillingford JM, Murchid NS, Larson CH: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006, 103:5466-5471
32. Arvisais EM, Romanelli A, Hou X, Davis JS: AKT-independent phosphorylation of TSC2 and activation of mTOR and ribosomal protein S6 kinase signaling by prostaglandin F2alpha. J Biol Chem 2006, 281:26904-26913
33. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ: Notch signals positively regulate activity of the mTOR pathway in T cell acute lymphoblastic leukemia. Blood 2007, 110:278-286
34. Moody CA, Scott RS, Amirghahari N, Nathan CA, Young LS, Dawson CW, Sixbey JW: Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A. J Virol 2005, 79:5499-5506
35. Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, Sausville EA, Sawai ET, Molinolo A, Gutkind JS, Montaner S: The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 2006, 10:133-143
36. Majewski M, Korecka M, Joergensen J, Fields L, Kossev P, Schuler W, Shaw L, Wasik MA: Immunosuppressive signal transduction inhibitor RAD suppresses growth of cells derived from post-transplant lymphoproliferative disorder at allograft protecting doses. Transplantation 2003, 75:1710-1717
37. Garcia VD, Bonamigo Filho JL, Neumann J, Fogliatto L, Geiger AM, Garcia CD, Barros V, Keitel E, Bittar AE, Ferrera des Santos A, Roithmann S: Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 2003, 16:202-206
38. Jiménez-Rivera C, Avitzur Y, Fecteau AH, Jones N, Grant D, Ng VL: Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant 2004, 8:243-248
39. Zaltzman JS, Prasad R, Chun K, Jothy S: Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus. Nephrol Dial Transplant 2005, 20:1748-1751
40. Cullis B, D'Souza R, McCullagh P, Harries S, Nicholls A, Lee R, Bingham C: Sirolimus-induced remission of post transplantation lymphoproliferative disorder. Am J Kidney Dis 2006, 47:e67-e72
41. Mohsin N, Budruddin M, Kamble P, Khalil M, Pakkyarra A, Jha A, Mohammed E, Ahmed H, Ahmed J, Thomas S, Campistol JM, Daar A: Complete regression of cutaneous B-cell lymphoma in a renal transplant patient after conversion from cyclosporin to sirolimus. Transplant Proc 2007, 39:1267-1271
42. Iaria G, Anselmo A, De Luca L, Manuelli M, Lucchesi C, Tariciotti L, Monaco A, Sforza D, Nigro F, Abruzzese E, Tisone G: Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: case reports. TransplantProc 2007, 39:2036-2037
43. Boratynska M, Smolska D: Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders. Transpl Int 2008, 21:605-608
44. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV: Conversion to sirolimus: a successful treatment for post transplantation Kaposi's sarcoma. Transplantation 2004, 77:760-762
45. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G: Sirolimus for Kaposi's sarcoma in renal- transplant recipients. N Engl J Med 2005, 352:317-1323
46. Castedo M, Roumier T, Blanco J, Ferri KF, Barretina J, Tintignac LA, Andreau K, Perfettini JL, Amendola A, Nardacci R, Leduc P, Ingber DE, Druillennec S, Roques B, Leibovitch SA, Vilella-Bach M, Chen J, Este JA, Modjtahedi N, Piacentini M, Kroemer G: Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J 2002, 21:4070-4080
47. Perfettini JL, Hospital V, Stahl L, Jungas T, Verbeke P, Ojcius DM: Cell death and inflam-mation during infection with the obligate intracellular pathogen. Chlamydia Biochim 2003, 85:763-769
48. Mounier N, Spina M, Gabarre J, Raphael M, Rizzardini G, Golfier JB, Vaccher E, Carbone A, Coiffier B, Chichino G, Bosly A, Tirelli U, Gisselbrecht C: AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 2006, 107:3832-3840
49. Bower M, Palmieri C, Dhillon T: AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 2006, 19:14-19